Shopping Cart
Remove All
Your shopping cart is currently empty
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Backorder | Backorder | |
| 5 mg | Inquiry | Backorder | Backorder |
| Description | Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity. |
| In vitro | Indatuximab ravtansine demonstrated cytotoxic effects in RPMI 8226, MOLP-8, and U266 cell lines (with significant CD138 expression) at concentrations ranging from 1 pM to 100 nM over five days. The IC50 values for RPMI 8226, MOLP-8, and U266 were 200 pM, 40 pM, and 20 pM, respectively. |
| In vivo | Indatuximab ravtansine (5.3-21.2 mg/kg; intravenous injection; single dose) suppresses tumor growth in multiple myeloma and enhances host survival in vivo. |
| Synonyms | nBT062-DM4, BT-062 |
| Cas No. | 1238517-16-2 |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.